WHAT IS CLAIMED IS:

1. A method of treating a retroviral infection by a retrovirus selected from the group consisting of HIV, HCMV, and HHV in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound represented by the following formula:

$$A \text{——} L \text{——} B$$

or a pharmaceutically acceptable acid-addition or base-addition salt thereof;

wherein:

component A is a substituted or unsubstituted aryl functional group, substituted or unsubstituted piperidyl, substituted or unsubstituted thiopheneyl;

component L is sulfonyl, sulfinyl or thio; and,

component B is a substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group.

2. The method of claim 1 wherein the retroviral infection being treated is an infection by a retrovirus selected from the group consisting of HIV-1, HIV-2, and HHV-6.

3. The method of claim 1 wherein the substituted or unsubstituted aryl functional group component A is a functional group of the following formula:



wherein Z is H, Cl, cyano, alkyl having from 1 to 15 carbon atoms, alkoxyalkyl having 2 or 3 carbon atoms; Y is H or a double bond to a carbon which is attached to R; and R is phenyl, biphenyl, benzyl, polycycloaryl, heteroaryl or phenyl substituted with 1 to 5 substituents which may be the same or different, the substituents being selected from the group consisting of lower alkyl having from 1 to 5 carbon atoms, halogen, nitro, methoxy, ethoxy, benzyloxy, methylenedioxy, 2,2-dichlorocyclopropyl, trifluoromethyl, methylsulfonyl, cyano and phenoxy.

4. The method of claim 1 wherein the substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group component B is 4-methylquinolyl, 8-ethyl-4-methylquinolyl or a functional group of the following formula:




wherein n is 0 or 1, $R_1$ and $R_2$ may be the same or different and are H, halogen, lower alkyl having from 1 to 4 carbon atoms, hydroxy, or nitro.

5. The method of claim 1 wherein the compound is selected from the group consisting of 2-(phenylmethylsulfonyl) pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)octylsulfonyl] pyridine-N-oxide, 2-[(2,5-dimethylphenyl)methylsulfonyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)ethyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl]-4-methylpyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl pyridine, 2-[1-(2,5-dimethylphenyl)methylthio]-3-

chloropyridine-N-oxide, 2-[phenylmethyl]thio-3-hydroxypyridine, 2-[(2,5-dimethylphenyl)methylthio] pyridine, 2-[(2,3,4,5,6-pentachlorophenyl)methylsulfonyl] pyridine N-oxide, 2[1-(phenylethyl)sulfonyl]-8-ethyl-4-methylquinoline, 2-[(3,4-dichlorophenyl)methylsulfonyl] pyridine-N-oxide, 2-[(4-(2,2-dichlorocyclopropyl)phenyl)methylsulfonyl] pyridine-N-oxide, 2-[(2,4,6-trimethylphenyl)methylsulfinyl] pyridine-N-oxide, 2-[(3-nitro-4-chlorophenyl)methylsulfonyl] pyridine-N-oxide, 2-[phenylmethylsulfinyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)propyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[(9-anthryl)methylsulfonyl] pyridine-N-oxide, 2-[4-((1,1dimethyl)propyl) phenyl)methylsulfonyl] pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)ethylthio]-4-methylquinoline, 2-[[(2,5dimethylphenyl)methyl]sulfonyl]-3-methylpyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.

6. The method of claim 1 wherein the compound is contained in a composition containing a pharmaceutically acceptable carrier.

7. A method of inhibiting the replication of a retrovirus selected from the group consisting HIV, HCMV, and HHV; the method comprising contacting the retrovirus with an effective amount a compound represented by the following formula:

$$A \text{ —— } L \text{ —— } B$$

or a pharmaceutically acceptable acid-addition or base-addition salt thereof;

wherein:

component A is a substituted or unsubstituted aryl functional group, substituted or unsubstituted piperidyl, substituted or unsubstituted thiopheneyl;

component L is sulfonyl, sulfinyl or thio; and,

component B is a substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group.

8. The method of claim 7 wherein the retrovirus whose replication is being inhibited is a retrovirus selected from the group consisting of HIV-1, HIV-2, and HHV-6.

9. The method of claim 7 wherein the substituted or unsubstituted aryl functional group of component A is a functional group of the following formula:




wherein Z is H, Cl, cyano, alkyl having from 1 to 15 carbon atoms, alkoxyalkyl having 2 or 3 carbon atoms; Y is H or a double bond to a carbon which is attached to R; and R is phenyl, biphenyl, benzyl, polycycloaryl, heteroaryl or phenyl substituted with 1 to 5 substituents which may be the same or different, the substituents being selected from the group consisting of lower alkyl having from 1 to 5 carbon atoms, halogen, nitro, methoxy, ethoxy, benzyloxy, methylenedioxy, 2,2-dichlorocyclopropyl, trifluoromethyl, methylsulfonyl, cyano and phenoxy.

10. The method of claim 7 wherein the substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group component B is 4-methylquinolyl, 8-ethyl-4-methylquinolyl or a functional group of the following formula:




wherein n is 0 or 1, $R_1$ and $R_2$ may be the same or different and are H, halogen, lower alkyl having from 1 to 4 carbon atoms, hydroxy, or nitro.

11. The method of claim 7 wherein the compound is selected from the group consisting of 2-(phenylmethylsulfonyl) pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)octylsulfonyl] pyridine-N-oxide, 2-[(2,5-dimethylphenyl)methylsulfonyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)ethyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl]-4-methylpyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl pyridine, 2-[1-(2,5-dimethylphenyl)methylthio]-3-chloropyridine-N-oxide, 2-[phenylmethyl]thio-3-hydroxypyridine, 2-[(2,5-dimethylphenyl)methylthio] pyridine, 2-[(2,3,4,5,6-pentachlorophenyl)methylsulfonyl] pyridine N-oxide, 2[1-(phenylethyl)sulfonyl]-8-ethyl-4-methylquinoline, 2-[(3,4-dichlorophenyl) methylsulfonyl] pyridine-N-oxide, 2-[(4-(2,2-dichlorocyclopropyl)phenyl)methylsulfonyl] pyridine-N-oxide, 2-[(2,4,6-trimethylphenyl)methylsulfinyl] pyridine-N-oxide, 2-[(3-nitro-4-chlorophenyl)methylsulfonyl] pyridine-N-oxide, 2-[phenylmethylsulfinyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)propyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[(9-anthryl) methylsulfonyl] pyridine-N-oxide, 2-[4-((1,1dimethyl)propyl) phenyl)methylsulfonyl] pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)ethylthio]-4-methylquinoline, 2-[[(2,5dimethylphenyl)

methyl]sulfonyl]-3-methylpyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.

12. The method of claim 7 wherein the compound is contained in a composition containing a pharmaceutically acceptable carrier.

13. A pharmaceutical composition useful for treating a retroviral infection by a retovirus selected from the group consisting of HIV, HCMV and HHV, in an afflicted host, comprising a therapeutically effective amount of the following compound:

or a pharmaceutically acceptable acid-addition and base-addition salt thereof;

wherein:

component A is a substituted or unsubstituted aryl functional group, substituted or unsubstituted piperidyl, or substituted or unsubstituted thiopheneyl;

component L is sulfonyl, sulfinyl or thio; and,

component B is a substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group; and

a pharmaceutically acceptable carrier

14. The composition of claim 13 wherein the substituted or unsubstituted aryl functional group component A is of the following formula:



wherein Z is H, Cl, cyano, alkyl having from 1 to 15 carbon atoms, alkoxyalkyl having 2 or 3 carbon atoms; Y is H or a double bond to a carbon which is attached to R; and R is phenyl, biphenyl, benzyl, polycycloaryl, heteroaryl or phenyl substituted with 1 to 5 substituents which may be the same or different, the substituents being selected from the group consisting of lower alkyl having from 1 to 5 carbon atoms, halogen, nitro, methoxy, ethoxy, benzyloxy, methylenedioxy, 2,2-dichlorocyclopropyl, trifluoromethyl, methylsulfonyl, cyano and phenoxy.

15. The composition of claim 13 wherein the substituted or unsubstituted aromatic nitrogen containing heteroaryl functional group component B is 4-methylquinolyl, 8-ethyl-4-methylquinolyl or a structure of the following formula:




wherein n is 0 or 1, $R_1$ and $R_2$ may be the same or different and are H, halogen, lower alkyl having from 1 to 4 carbon atoms, hydroxy, or nitro.

16. The composition of claim 13 wherein the compound is selected from the group consisting of 2-(phenylmethylsulfonyl) pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl) octylsulfonyl] pyridine-N-oxide, 2-[(2,5-dimethylphenyl)methylsulfonyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)ethyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl]-4-methylpyridine-N-oxide, 2-[1-(2,5-

dimethylphenyl)chloromethyl]sulfonyl] pyridine, 2-[1-(2,5-dimethylphenyl)methylthio]-3-chloropyridine-N-oxide, 2-[phenylmethyl]thio-3-hydroxypyridine, 2-[(2,5-dimethylphenyl) methylthio] pyridine, 2-[(2,3,4,5,6-pentachlorophenyl)methylsulfonyl] pyridine N-oxide, 2[1-(phenylethyl)sulfonyl]-8-ethyl-4-methylquinoline, 2-[(3,4-dichlorophenyl)methylsulfonyl] pyridine-N-oxide, 2-[(4-(2,2-dichlorocyclopropyl)phenyl)methylsulfonyl] pyridine-N-oxide, 2-[(2,4,6-trimethylphenyl)methylsulfinyl] pyridine-N-oxide, 2-[(3-nitro-4-chlorophenyl) methylsulfonyl] pyridine-N-oxide, 2-[phenylmethylsulfinyl] pyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)propyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[(9-anthryl)methylsulfonyl] pyridine-N-oxide, 2-[4-((1,1dimethyl)propyl) phenyl)methylsulfonyl] pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)ethylthio]-4-methylquinoline, 2-[[(2,5dimethylphenyl)methyl]sulfonyl]-3-methylpyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.

17. A method of treating an HIV infection in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound selected from the group consisting of 2-[[1-(2,5-dimethylphenyl)ethyl]sulfonyl]-3-methylpyridine-N-oxide, 2-[[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl]-4-methylpyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)chloromethyl]sulfonyl] pyridine, 2-[1-(2,5-dimethylphenyl)methylthio]-3-chloropyridine-N-oxide, 2-[phenylmethyl]thio-3-hydroxypyridine, 2-[(2,3,4,5,6-pentachlorophenyl) methylsulfonyl] pyridine N-oxide, 2[1-(phenylethyl)sulfonyl]-8-ethyl-4-methylquinoline, 2-[(3,4-dichlorophenyl)methylsulfonyl] pyridine-N-oxide, 2-[(4-(2,2-dichlorocyclopropyl)phenyl)methylsulfonyl] pyridine-N-oxide, 2-[(2,4,6-trimethylphenyl) methylsulfinyl] pyridine-N-oxide ,2-[(3-nitro-4-chlorophenyl)methylsulfonyl] pyridine-N-oxide,

ex4 comp 16

2-[phenylmethylsulfinyl] pyridine-N-oxide, 2-[[(2,5dimethylphenyl)methyl]sulfonyl]-3-methylpyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.

18. A method of treating an HCMV infection in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound selected from the group consisting of 2-[(2,5-dimethylphenyl)methylthio] pyridine, 2-[1-(2,5-dimethylphenyl)octylsulfonyl] pyridine-N-oxide (ex1 comp 4), 2-[[1-(2,5-dimethylphenyl)propyl]sulfonyl]-3-methylpyridine-N-oxide (ex6 comp 70), 2-[(9-anthryl)methylsulfonyl] pyridine-N-oxide, 2-[4-((1,1dimethyl)propyl) phenyl)methylsulfonyl] pyridine-N-oxide, 2-[1-(2,5-dimethylphenyl)ethylthio]-4-methylquinoline and pharmaceutically acceptable acid-addition and base-addition salts thereof.

19. A method of treating an HHV-6 infection in an afflicted host which comprises administering to the host a therapeutically effective amount of a compound selected from the group consisting of 2-[(2,5-dimethylphenyl)methylsulfonyl] pyridine-N-oxide (ex3 (comp 10)), and 2-(phenylmethylsulfonyl) pyridine-N-oxide and pharmaceutically acceptable acid-addition and base-addition salts thereof.